Stephen R. Marder

Stephen R. Marder is a Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences at the UCLA School of Medicine. He holds the Dr. Daniel X. Freedman Administrative Chair in Academic Psychiatry and serves as Principal or Co-Principal Investigator on multiple NIH-funded research projects focused on schizophrenia treatment and outcomes.

Dr. Marder's research primarily focuses on schizophrenia, particularly negative symptoms, cognitive impairment, and antipsychotic medication development. His work examines treatment approaches for negative symptoms, clinical trial design methodologies, measurement tools for assessing symptoms, and the relationship between symptom domains and functional outcomes in schizophrenia. He has been instrumental in developing assessment instruments and advancing the understanding of how to properly evaluate treatment effects in clinical trials.

His recent publications reveal a strong emphasis on novel assessment methods, particularly remote and digital measurement tools for negative symptoms, new pharmacological approaches targeting negative symptoms and cognitive impairment, and critical examination of clinical trial design and outcome measures in schizophrenia research. There's a clear trend toward developing more precise measurement tools and challenging conventional paradigms in schizophrenia treatment research.

Dr. Marder has served as Principal or Co-Principal Investigator on numerous NIH-funded projects including 'Enhancing Community Integration for Homeless Veterans,' 'Enhancing Social Cognitive Training with Oxytocin,' and 'Opportunities for Innovative Drug Development for Schizophrenia.' His research portfolio demonstrates sustained commitment to advancing schizophrenia treatment through both pharmacological and psychosocial interventions.

He leads or participates in multiple research teams focused on schizophrenia treatment development, negative symptoms assessment, and cognitive impairment. His work often involves multi-site collaborations with researchers across academic institutions and pharmaceutical partners developing novel treatments for schizophrenia.